Candesartan cilexetil/rosuvastatin - Alvogen

Drug Profile

Candesartan cilexetil/rosuvastatin - Alvogen

Alternative Names: Candesartan cilexetil/rosuvastatin calcium; DP R208; Rosuvastatin/candesartan

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alvogen
  • Class Antihyperlipidaemics; Antihypertensives; Benzimidazoles; Fluorobenzenes; Heart failure therapies; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypertension
  • No development reported Cardiovascular disorders

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in South Korea
  • 01 Oct 2016 Alvogen Korea completes a phase III trial in Hypertension in South Korea (PO) (NCT02770261)
  • 31 May 2016 Alvogen Korea completes a phase I pharmacokinetics trial in Healthy male volunteers in South Korea (unspecified route) (NCT02709187)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top